Peter Attia· MD
we know that an apoe4 carrier possibly with type 2 diabetes may have worse outcomes than an ap4 carrier without
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
we know that an apoe4 carrier possibly with type 2 diabetes may have worse outcomes than an ap4 carrier without
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
if you take two unhealthy people type 2 diabetes nafld profound insulin resistance One e41 E3 with the same APO B it could be that those other factors create more of a gap between those people on a kaplan-meyer curve